[HTML][HTML] Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma
A WellsSamuel Jr, L AsaSylvia, B EvansDouglas… - Thyroid, 2015 - liebertpub.com
Abstract Introduction: The American Thyroid Association appointed a Task Force of experts
to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the …
to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the …
Medullary thyroid cancer: management guidelines of the American Thyroid Association
Background: Inherited and sporadic medullary thyroid cancer (MTC) is an uncommon and
challenging malignancy. The American Thyroid association (ATA) chose to create specific …
challenging malignancy. The American Thyroid association (ATA) chose to create specific …
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
V Subbiah, MI Hu, LJ Wirth, M Schuler… - The lancet Diabetes & …, 2021 - thelancet.com
Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
SA Wells Jr, BG Robinson, RF Gagel… - Journal of clinical …, 2012 - ascopubs.org
Purpose There is no effective therapy for patients with advanced medullary thyroid
carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular …
carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular …
Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models
O Tohyama, J Matsui, K Kodama… - Journal of thyroid …, 2014 - Wiley Online Library
Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor
(VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib …
(VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib …
[HTML][HTML] Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
M Schlumberger, R Elisei, S Müller, P Schöffski… - Annals of …, 2017 - Elsevier
Background Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib)
in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement …
in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement …
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma …
Pheochromocytomas, intra-adrenal paraganglioma, and extra-adrenal sympathetic and
parasympathetic paragangliomas are neuroendocrine tumors derived from adrenal …
parasympathetic paragangliomas are neuroendocrine tumors derived from adrenal …
New developments in the diagnosis and treatment of thyroid cancer
DF Schneider, H Chen - CA: a cancer journal for clinicians, 2013 - Wiley Online Library
Answer questions and earn CME/CNE Thyroid cancer exists in several forms. Differentiated
thyroid cancers include those with papillary and follicular histologies. These tumors exist …
thyroid cancers include those with papillary and follicular histologies. These tumors exist …
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update
SA Wells Jr, F Pacini, BG Robinson… - The Journal of Clinical …, 2013 - academic.oup.com
Context: Over the last decade, our knowledge of the multiple endocrine neoplasia (MEN)
type 2 syndromes MEN2A and MEN2B and familial medullary thyroid carcinoma (FMTC) has …
type 2 syndromes MEN2A and MEN2B and familial medullary thyroid carcinoma (FMTC) has …
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer
SA Wells Jr, JE Gosnell, RF Gagel, J Moley… - Journal of Clinical …, 2010 - ascopubs.org
Purpose There is no effective therapy for patients with distant metastasis of medullary thyroid
carcinoma (MTC). Activating mutations in the RET proto-oncogene cause hereditary MTC …
carcinoma (MTC). Activating mutations in the RET proto-oncogene cause hereditary MTC …